Will GSK’s Walmsley Be Feared As ‘Witty But Worse’?
Executive Summary
The announcement that Emma Walmsley is to take over from Sir Andrew Witty as CEO of GSK is surprising in more ways than one.
You may also be interested in...
Novartis Rejiggers Pharma To Favor Oncology
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.
Witty's Successor: The Shortlist
"The board will now start a formal search for a successor and will consider internal and external candidates for the role," said GlaxoSmithKline PLC's chair Sir Philip Hampton, and the games begin.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.